Center for Integrative Biology, Faculty of Sciences, Universidad Mayor, Santiago 8580745, Chile.
Geroscience Center for Brain Health and Metabolism, Santiago 8580745, Chile.
Int J Mol Sci. 2021 Jan 11;22(2):651. doi: 10.3390/ijms22020651.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy whose chemoresistance and relapse persist as a problem despite significant advances in its chemotherapeutic treatments. Mitochondrial metabolism has emerged as an interesting therapeutic target given its essential role in maintaining bioenergetic and metabolic homeostasis. T-ALL cells are characterized by high levels of mitochondrial respiration, making them suitable for this type of intervention. Mitochondrial function is sustained by a constitutive transfer of calcium from the endoplasmic reticulum to mitochondria through the inositol 1,4,5-trisphosphate receptor (InsP3R), making T-ALL cells vulnerable to its inhibition. Here, we determine the bioenergetic profile of the T-ALL cell lines CCRF-CEM and Jurkat and evaluate their sensitivity to InsP3R inhibition with the specific inhibitor, Xestospongin B (XeB). Our results show that T-ALL cell lines exhibit higher mitochondrial respiration than non-malignant cells, which is blunted by the inhibition of the InsP3R. Prolonged treatment with XeB causes T-ALL cell death without affecting the normal counterpart. Moreover, the combination of XeB and glucocorticoids significantly enhanced cell death in the CCRF-CEM cells. The inhibition of InsP3R with XeB rises as a potential therapeutic alternative for the treatment of T-ALL.
T 细胞急性淋巴细胞白血病(T-ALL)是一种侵袭性血液系统恶性肿瘤,尽管在化疗治疗方面取得了重大进展,但仍然存在化疗耐药和复发的问题。线粒体代谢因其在维持生物能量和代谢平衡方面的重要作用而成为一个有趣的治疗靶点。T-ALL 细胞的特点是线粒体呼吸水平高,因此适合进行这种类型的干预。线粒体功能通过内质网通过肌醇 1,4,5-三磷酸受体(InsP3R)向线粒体持续传递钙来维持,这使得 T-ALL 细胞容易受到其抑制的影响。在这里,我们确定了 T-ALL 细胞系 CCRF-CEM 和 Jurkat 的生物能量特征,并评估了它们对 InsP3R 抑制剂 Xestospongin B(XeB)的敏感性。我们的研究结果表明,T-ALL 细胞系的线粒体呼吸水平高于非恶性细胞,InsP3R 的抑制可使这种呼吸水平降低。长时间用 XeB 处理会导致 T-ALL 细胞死亡,而不会影响正常细胞。此外,XeB 和糖皮质激素的联合使用可显著增强 CCRF-CEM 细胞的细胞死亡。用 XeB 抑制 InsP3R 可能成为治疗 T-ALL 的一种潜在治疗选择。